3
Announcements
Trials
Browse
Landscape
Status
Available
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
25
Observational
3
Expanded_access
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Interventions
3-Iodobenzylguanidine
2
Cyclophosphamide
2
Gemcitabine
2
Insulin Infusion Systems
2
Powders
2
Suspensions
2
balstilimab
2
leronlimab
2
ruxolitinib
2
talquetamab
2
Abiraterone Acetate
1
Alpelisib
1
Androgen Antagonists
1
Asparaginase
1
Bone Marrow Transplantation
1
Capecitabine
1
Docetaxel
1
Eflornithine
1
HMPL-013
1
Hydrocortisone
1
Immunotherapy, Adoptive
1
LY3023414
1
Magnetic Resonance Spectroscopy
1
Methionine
1
Nivolumab
1
Paclitaxel
1
Peripheral Blood Stem Cell Transplantation
1
Prednisolone
1
Prednisone
1
Proton Pump Inhibitors
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Expanded_access
×
asciminib
×
1 year
×
Clear all
NCT04360005
2025-12-05
Managed Access Programs for ABL001, Asciminib
Novartis
Available